{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-199706","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2025-09-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.307841+00:00","generated_at":"2026-05-17T06:57:22.191815+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"FDA accepts Corcept's NDA for relacorilant in platinum-resistant ovarian cancer; PDUFA July 11, 2026","bullets":["FDA accepted Corcept's NDA for relacorilant in platinum-resistant ovarian cancer with a PDUFA date of July 11, 2026.","NDA based on positive Phase 3 ROSELLA and Phase 2 data showing improved PFS and OS without biomarker selection.","Relacorilant plus nab-paclitaxel was well-tolerated; adverse events similar to nab-paclitaxel monotherapy.","CEO Joseph Belanoff: 'FDA acceptance brings us closer to offering a much-needed treatment option for this dire disease.'","Relacorilant may redefine platinum-resistant ovarian cancer treatment, Corcept states."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-199706","json":"https://secwatch.observer/filing/0001193125-25-199706.json","markdown":"https://secwatch.observer/filing/0001193125-25-199706.md","text":"https://secwatch.observer/filing/0001193125-25-199706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000119312525199706/0001193125-25-199706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000119312525199706/d947259d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:57:22.191815+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}